SARS Spike Antibody |
24216 |
SAB |
100ul |
EUR 479 |
Human IgG antibody Laboratories manufactures the anti sars spike protein antibody reagents distributed by Genprice. The Anti Sars Spike Protein Antibody reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Antibody. Other Anti products are available in stock. Specificity: Anti Category: Sars Group: Spike Protein
SARS Spike Antibody |
SAB |
100ul |
EUR 479 |
SARS Spike Antibody |
SAB |
100ul |
EUR 468 |
SARS-CoV spike protein Antibody |
Abbexa |
100 ug |
EUR 1028.4 |
|
SARS-CoV spike protein Antibody |
Abbexa |
100 ug |
EUR 1028.4 |
|
SARS-CoV Spike Antibody |
SAB |
100ul |
EUR 1039 |
SARS-CoV Spike Antibody |
SAB |
100ul |
EUR 1039 |
Spike Protein information
SARS-CoV Spike Antibody |
21807 |
SAB |
100ul |
EUR 1039 |
SARS-CoV Spike Antibody |
21808 |
SAB |
100ul |
EUR 1039 |
SARS-CoV Spike Antibody |
21809 |
SAB |
100ul |
EUR 1039 |
SARS-CoV Spike Antibody |
21810 |
SAB |
100ul |
EUR 1039 |
SARS-CoV Spike Antibody |
21811 |
SAB |
100ul |
EUR 1039 |
SARS-CoV Spike Antibody |
21812 |
SAB |
100ul |
EUR 1039 |
SARS-CoV Spike Antibody |
3225-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3225-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3219-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3219-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3221-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3221-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3223-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3223-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
Anti-SARS Spike Protein |
18950 |
Genovis AB |
100ul |
EUR 551 |
Anti-SARS Spike Protein |
18951 |
Genovis AB |
100ul |
EUR 551 |
Anti-SARS Spike Protein |
18952 |
Genovis AB |
100ul |
EUR 551 |